Stanca, D.M., Mărginean, I.C., Soritau, O., Dragoș, C., Mărginean, M., Mureșanu, D.F. & Rafila, A. (2015) Journal of Cellular and Molecular Medicine [Q1]

Publicat: 17 Septembrie 2021

Stanca, D.M., Mărginean, I.C., Soritau, O., Dragoș, C., Mărginean, M., Mureșanu, D.F. & Rafila, A. (2015) GFAP and antibodies against NMDA receptor subunit NR 2 as biomarkers for acute cerebrovascular diseases. Journal of Cellular and Molecular Medicine, 19(9), 2253-2261.

DOI: https://doi.org/10.1111/jcmm.12614

✓ Publisher: Wiley
✓ Categories: Cell biology; Medicine, research & experimental
✓ Article Influence Score (AIS): 1.144 (2015) / Q1 in Medicine, research & experimental; Q2 in Cell biology

Abstract: We studied whether the serum levels of glial fibrillary acidic protein (GFAP) and of antibodies against the N-methyl-d-aspartate receptor subunit NR2 (NR2 RNMDA) can discriminate between intracerebral haemorrhage (ICH) and ischaemic stroke (IS) in stroke patients. We prospectively recruited patients with suspected stroke (72 confirmed) and 52 healthy controls. The type of brain lesion (ICH or IS) was established using brain imaging. The levels of GFAP and of antibodies against NR2 RNMDA were measured in blood samples obtained within 12 hrs after stroke onset and 24, 48 and 72 hrs and 1 and 2 weeks later using ELISA immunoassay. Improvement in diagnostic performance was assessed in logistic regression models designed to predict the diagnosis and the type of stroke. GFAP peaks early during haemorrhagic brain lesions (at significantly higher levels), and late in ischaemic events, whereas antibodies against NR2 RNMDA have significantly higher levels during IS at all time-points. Neither of the two biomarkers used on its own could sufficiently discriminate patients, but when they are used in combination they can differentiate at 12 hrs after stroke, between ischaemic and haemorrhagic stroke with a sensitivity and specificity of 94% and 91%, respectively.

inapoi la stiri   vezi evenimentele   home